Abstract

New strategies against antibiotic-resistant bacterial pathogens are urgently needed but are not within reach. Here, we present in vitro and in vivo antimicrobial activity of TSPphg, a novel phage lysin identified from extremophilic Thermus phage TSP4 by sequencing its whole genome. By breaking down the bacterial cells, TSPphg is able to cause bacteria destruction and has shown bactericidal activity against both Gram-negative and Gram-positive pathogenic bacteria, especially antibiotic-resistant strains of Klebsiella pneumoniae, in which the complete elimination and highest reduction in bacterial counts by greater than 6 logs were observed upon 50 μg/mL TSPphg treatment at 37 °C for 1 h. A murine skin infection model further confirmed the in vivo efficacy of TSPphg in removing a highly dangerous and multidrug-resistant Staphylococcus aureus from skin damage and in accelerating wound closure. Together, our findings may offer a therapeutic alternative to help fight bacterial infections in the current age of mounting antibiotic resistance, and to shed light on bacteriophage-based strategies to develop novel anti-infectives.

Highlights

  • Bacterial resistance has been reported in all WHO regions and identified for every antimicrobial drug developed to date [1,2]

  • 50 μg/mL prepared in phosphate-buffered saline (PBS) was first heated at different temperatures for 30 min; its lytic activity was measured by the standard turbidity reduction assay against 108 of Thermus sp

  • We examined the antibacterial activity of TSPphg against nine different antibiotic-resistant strains of K. pneumoniae that are exceedingly hard to deal to most antibiotics, in recent years infections caused by K. pneumoniae have become progressively difficult to treat [26,27]

Read more

Summary

Introduction

Bacterial resistance has been reported in all WHO regions and identified for every antimicrobial drug developed to date [1,2]. The recent increase in bacterial strains showing resistance to almost all classes of antibiotics commonly used in human medicine has become a serious threat to public health worldwide [3,4]. When applied exogenously in the treatment of bacterial infections, recombinant phage lysins can exhibit effective antibacterial performance to their native counterparts, supporting the wide application of these agents in the fields of biotechnology, medicine, food and agriculture [11,12]. We identified a novel phage lysin named TSPphg and assessed its in vitro and in vivo antibacterial activity against a panel of antibiotic-resistant strains

Ethics Statement
Bacterial Strains and Culture Conditions
Genome Sequencing and Annotation
Production and Purification of Recombinant Protein TSPphg
In Vitro Antibacterial Activity Assays
Mouse Model of Skin Damage and TSPphg Treatment
Statistical Analysis
Identification of TSPphg
Bactericidal
Time-kill
Antibacterial
TSPphg Accelerates Wound Healing in a Murine Skin Infection Model
SEM Observations of the Bacteriolytic Activity of of TSPphg
Scanning
Discussion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call